{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:54:52Z","timestamp":1762102492228},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>Circulating tumour cells (CTCs) from liquid biopsies provide an exceptional opportunity to obtain real-time tumour information and are under current investigation in several cancers, including cutaneous melanoma, but face significant drawbacks in terms of non-standardised methodology, low viable cell numbers and accuracy of CTC identification. In this pilot study, we report that chemosensitivity assays using liquid biopsy-derived metastatic melanoma (MM) CTCs, from 7 patients with stage IIIC, <jats:italic>BRAF<\/jats:italic> wild-type metastatic melanomas, localized exclusively to the pelvic region, un-eligible for immunotherapy and treated with melphalan hypoxic pelvic perfusion (HPP), is both feasible and useful in predicting response to therapy. Viable MM CTCs (&gt;\u20095 cells\/ml for all 7 blood samples), enriched by transient culture, were characterised in flow cytometry-based Annexin V-PE assays for chemosensitivity to several drugs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Using melphalan as a standard, chemosensitivity cut-off values of\u2009&gt;\u200960% cell death, were predictive of patient RECIST 1.1 response to melphalan HPP therapy, associated with calculated 100% sensitivity, 66.67% specificity, 33.33% positive predictive, 100% negative predictive, and 71.43% accuracy values. We propose that the methodology in this study is both feasible and has potential value in predicting response to therapy, setting the stage for a larger study.<\/jats:p>\n<jats:p><jats:italic>Trial registration<\/jats:italic> Clinical Trials.gov Identifier NCT01920516; date of trial registration: August 6, 2013<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13104-020-05021-5","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T03:03:14Z","timestamp":1585018994000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study"],"prefix":"10.1186","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct01920516","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stefano","family":"Guadagni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giammaria","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Papasotiriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Apostolou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Masedu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta Rossella","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Reay","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"5021_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.soc.2010.09.008","volume":"20","author":"RS Turley","year":"2011","unstructured":"Turley RS, Raymond AK, Tyler DS. Regional treatment strategies for in-transit melanoma metastasis. Surg Oncol Clin N Am. 2011;20:79\u2013103.","journal-title":"Surg Oncol Clin N Am"},{"key":"5021_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4329\/wjr.v5.i2.25","volume":"5","author":"AT Trout","year":"2013","unstructured":"Trout AT, Rabinowitz RS, Platt JF, Elsayes KM. Melanoma metastases in the abdomen and pelvis: frequency and patterns of spread. World J Radiol. 2013;5:25\u201332.","journal-title":"World J Radiol."},{"key":"5021_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jss.2017.03.066","volume":"215","author":"S Guadagni","year":"2017","unstructured":"Guadagni S, Fiorentini G, Clementi M, et al. Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis. J Surg Res. 2017;215:114\u201324.","journal-title":"J Surg Res"},{"key":"5021_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1063::AID-CNCR17>3.0.CO;2-E","volume":"88","author":"XD Dong","year":"2000","unstructured":"Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer. 2000;88:1063\u201371.","journal-title":"Cancer"},{"key":"5021_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.168912","author":"RL Read","year":"2019","unstructured":"Read RL, Thompson JF. Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. Expert Rev Clin Pharmacol. 2019. https:\/\/doi.org\/10.1080\/17512433.2019.168912.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"5021_CR6","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","volume":"22","author":"JF Thompson","year":"2015","unstructured":"Thompson JF, Agarwala SS, Smithers BM, Ross MI, Scoggins CR, Coventry BJ, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22:2135\u201342.","journal-title":"Ann Surg Oncol"},{"key":"5021_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2017","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2017;36:1658\u201367.","journal-title":"J Clin Oncol"},{"key":"5021_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/bjs.8749","volume":"99","author":"L Campana","year":"2012","unstructured":"Campana L, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg. 2012;99:821\u201330.","journal-title":"Br J Surg"},{"key":"5021_CR9","first-page":"127","volume":"2","author":"C Carac\u00f2","year":"2015","unstructured":"Carac\u00f2 C, Marone U, Simeone E, Grimaldi AM, Botti G, Del Giudice M, et al. Electrochemotherapy in melanoma patients: a single institution experience. Mel Manag. 2015;2:127\u201332.","journal-title":"Mel Manag."},{"key":"5021_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.015","author":"C Garbe","year":"2019","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, On behalf of the European Dermatology Forum (EDF), The European Association of Dermato-Oncology (EADO), The European Organization for Research and Treatment of Cancer (EORTC), et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u2014update 2019. Eur J Cancer. 2019. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.015.","journal-title":"Eur J Cancer."},{"key":"5021_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/PPO.0b013e31824b241a","volume":"18","author":"A Hong","year":"2012","unstructured":"Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J. 2012;18:203\u20137.","journal-title":"Cancer J"},{"key":"5021_CR12","first-page":"61","volume-title":"Induction chemotherapy. Systemic and locoregional","author":"G Fiorentini","year":"2016","unstructured":"Fiorentini G, Cantore M, Montagnani F, Mambrini A, D\u2019Alessandro M, Guadagni S. The role of hypoxia and hyperthermia in chemotherapy. In: Aigner KR, Stephens FO, editors. Induction chemotherapy. Systemic and locoregional. 2nd ed. Berlin: Springer-Verlag; 2016. p. 61\u201371.","edition":"2"},{"key":"5021_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s13104-017-2738-y","volume":"10","author":"S Guadagni","year":"2017","unstructured":"Guadagni S, Palumbo G, Fiorentini G, Clementi M, Marsili L. Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability. BMC Res Notes. 2017;10:411.","journal-title":"BMC Res Notes"},{"key":"5021_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/CMR.0000000000000367","volume":"27","author":"S Guadagni","year":"2017","unstructured":"Guadagni S, Fiorentini G, Clementi M, et al. MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study. Melanoma Res. 2017;27:439\u201347.","journal-title":"Melanoma Res."},{"key":"5021_CR15","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3390\/ijms18112382","volume":"18","author":"S Guadagni","year":"2017","unstructured":"Guadagni S, Fiorentini G, Clementi M, et al. Does locoregional chemotherapy still matter in the treatment of advanced pelvic melanoma? Int J Mol Sci. 2017;18:2382. https:\/\/doi.org\/10.3390\/ijms18112382.","journal-title":"Int J Mol Sci"},{"key":"5021_CR16","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2019-0010","author":"EN Tie","year":"2019","unstructured":"Tie EN, Lai-Kwon JE, Gyorki DE. Systemic therapies for unresectable locoregional melanoma: a significant area of need. Melanoma Manag. 2019. https:\/\/doi.org\/10.2217\/mmt-2019-0010.","journal-title":"Melanoma Manag."},{"key":"5021_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S1470-2045(16)30368-0","volume":"17","author":"NI Khushalani","year":"2016","unstructured":"Khushalani NI, Sondak VK. Are we there yet? Prolonged MAPK inhibition in BRAF V600-mutant melanoma. Lancet Oncol. 2016;17:1178\u20139.","journal-title":"Lancet Oncol."},{"key":"5021_CR18","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1002\/cncr.28851","volume":"120","author":"MM Chan","year":"2014","unstructured":"Chan MM, Haydu LE, Menzies AM, et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer. 2014;120:3142\u201353.","journal-title":"Cancer"},{"key":"5021_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topollian","year":"2014","unstructured":"Topollian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u201330.","journal-title":"J Clin Oncol"},{"key":"5021_CR20","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600\u20139.","journal-title":"JAMA"},{"key":"5021_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/14740338.2016.1175430","volume":"15","author":"A Daud","year":"2016","unstructured":"Daud A, Nandoskar P. Pembrolizumab for melanoma-safety profile and future trends. Expert Opin Drug Saf. 2016;15:727\u20139.","journal-title":"Expert Opin Drug Saf."},{"key":"5021_CR22","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","volume":"123","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904\u201311.","journal-title":"Cancer"},{"key":"5021_CR23","first-page":"36","volume":"3","author":"N Karachaliou","year":"2015","unstructured":"Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R. Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med. 2015;3:36.","journal-title":"Ann Transl Med."},{"key":"5021_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00432-019-03046-3","volume":"146","author":"S Guadagni","year":"2020","unstructured":"Guadagni S, Fiorentini G, De Simone M, et al. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study. J Cancer Res Clin Oncol. 2020;146:205\u201319.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5021_CR25","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/cancers11101595","volume":"11","author":"SB Lim","year":"2019","unstructured":"Lim SB, Lim CT, Lim W-T. Single-cell analysis of circulating tumor cells: why heterogeneity matters. Cancers. 2019;11:1595. https:\/\/doi.org\/10.3390\/cancers11101595.","journal-title":"Cancers."},{"key":"5021_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00279","author":"A Beasley","year":"2018","unstructured":"Beasley A, Isaacs T, Khattak MA. Clinical application of circulating tumor cells and circulating tumor DNA in uveal melanoma. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/PO.17.00279.","journal-title":"JCO Precis Oncol."},{"key":"5021_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40709-017-0068-9","volume":"24","author":"P Apostolou","year":"2017","unstructured":"Apostolou P, Ntanovasilis DA, Papasotiriou I. Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96\u00a0h after sample collection. J Biol Res Thessalon. 2017;24:11.","journal-title":"J Biol Res Thessalon."},{"key":"5021_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2050-6511-14-18","volume":"14","author":"P Apostolou","year":"2013","unstructured":"Apostolou P, Toloudi M, Chatziioannou M, et al. Anvirzel\u2122 in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines. BMC Pharmacol Toxicol. 2013;14:18.","journal-title":"BMC Pharmacol Toxicol."},{"key":"5021_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/030089160609200506","volume":"92","author":"S Guadagni","year":"2006","unstructured":"Guadagni S, Kanavos E, Schietroma M, Fiorentini G, Amicucci G. Selected hypoxic stop-flow perfusions: indication and limits. Tumori. 2006;92:402\u20136.","journal-title":"Tumori."},{"key":"5021_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J. New response valuation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer."},{"key":"5021_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","volume":"468","author":"D Asante","year":"2020","unstructured":"Asante D, Calaprea L, Ziman L, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time? Cancer Lett. 2020;468:59\u201371.","journal-title":"Cancer Lett"},{"key":"5021_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.21873\/anticanres.13113","volume":"39","author":"J-H Kim","year":"2019","unstructured":"Kim J-H, Yoon YS, Kim JC, Kim Y-M. Assessment of the applicability of Integrative tumor response assays in advanced epithelial ovarian cancer. Anticancer Res. 2019;39:313\u20138.","journal-title":"Anticancer Res"},{"key":"5021_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jpsychires.2010.10.008","volume":"45","author":"AC Leon","year":"2011","unstructured":"Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45:626\u20139.","journal-title":"J Psychiatr Res"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-020-05021-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:05:12Z","timestamp":1628615112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-05021-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5021"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-05021-5","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This project has been performed in accordance with the Declaration of Helsinki and has been approved by the ethics committee of ASL n.1, Abruzzo, Italy (Chairperson: G. Piccioli; protocol number 10\/CE\/2018; date of approval: 19 July, 2018 (n. 1419), L\u2019Aquila, Italy). Written informed consent was obtained from each of the 7 patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript does not contain any individual person data, so consent for publication is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}